WED 188 Pangaea 2.0 interim results: switching to fingolimod

ObjectivesPresent first interim results of PANGAEA 2.0 including effectiveness data of patients switching from other oral disease modifying therapies (oDMTs; dimethyl fumarate and teriflunomide) to fingolimod.MethodsPANGAEA 2.0 is an ongoing non-interventional study. As of January 2017 PANGAEA 2.0 included 1419 patients, 1116 were included in this analysis of which 183 switched from other oDMTs to fingolimod.ResultsSlight differences were observed in the number of relapses 12 months (M) before baseline (mean ± SD) (1.4±1.0 vs 1.6±1.0), the EDSS (2.2±1.6 vs 2.4±1.7) and the MSSS (3.5±2.5 vs 3.8±2.5). 67.4% of the patients switched from dimethyfumarate to fingolimod and 32.6% from teriflunomide. For 30.2% of the patients fingolimod was the second therapy since diagnosis. The annualized relapse rate (ARR,±95% CI) 6M after switch to fingolimod was reduced from 1.6±0.22 to 0.2±0.05 for the patients switching from other oDMTs. For all patients the ARR was reduced from 1.3±0,06 to 0,14±0,02. The EDSS (±95% CI) remained stable at 2.4±0.37 (2.5±0.50 respectively).ConclusionsThese data indicate that active disease patients switching from dimethyl fumarate or teriflunomide to fingolimod can benefit from this switch.Disclaimerpreviously presented at ECTRIMS 2017.